Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: A nationwide population-based study
Introduction
Primary total hip arthroplasty (THA) is a well-documented treatment of hip joint arthritis providing pain relief and improved function. The most frequent reasons for revision are aseptic loosening of the components, deep infections, and dislocation [1]. As revision surgery is associated with increased rates of complications and morbidity every effort should be directed at identifying factors that could increase the longevity of primary THA.
Bisphosphonates are widely used for the treatment of osteoporosis. They inhibit bone resorption, increase bone density and reduce the risk of fractures [2]. Further, according to experimental and clinical studies bisphosphonates have been associated with increased implant fixation, decreased prosthetic migration [3], [4], [5], decreased periprosthetic bone loss, and reduced particle induced bone resorption [6]. It has therefore been proposed that bisphosphonates may improve the longevity of total joint replacements [6]. However, so far there have been a lack of large-scale epidemiological studies and it is therefore uncertain if the proposed effects of bisphosphonates really translate into clinically relevant improvements in implant durability.
We therefore conducted this nested case–control study to examine the association between the use of bisphosphonates and the risk of revision after primary THA using comprehensive data from population-based nationwide medical databases in Denmark.
Section snippets
Materials and methods
In Denmark, the National Health Service provides tax-supported healthcare for all inhabitants, allowing free access to general practitioners and hospitals. In addition, part of the costs of prescribed drugs is covered by the healthcare system.
Results
The distribution of covariates among matched cases and controls are presented in Table 1. Statistical significant differences were found for a number of covariates including region of residence, congestive heart failure, chronic pulmonary disease, liver disease, Charlson comorbidity index score, implant fixation technique, diagnosis for primary THA surgery, and previous diagnosis of osteoporosis or osteoporotic fracture.
The 10-year THA failure rate for the underlying cohort of osteoporosis
Discussion
In this first large-scale epidemiological study on bisphosphonates use and revision risk following primary THA, we found an increased risk of revision due to deep infection in postoperative users of bisphosphonates. However, long-term use of bisphosphonates was not associated with the risk of revision due to deep infections. Further, we found evidence of an increased risk of revision in short-term postoperative users whereas; the risk of revision was reduced among long-term postoperative users
Acknowledgments
The authors thank the Danish Rheumatism Association, the Korning Foundation and the Augustinus Foundation for their financial support. The funding sources did not play a role in the study. The authors thank Anne Hjelm, secretary for the Danish Hip Arthroplasty Registry.
References (34)
- et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
The direct medical costs of osteoporosis for American women aged 45 and older, 1986
Bone
(1988) - et al.
Use of diuretics and risk of implant failure after primary total hip arthroplasty: a nationwide population-based study
Bone
(9/2009) - et al.
Stimulation of bone formation by zoledronic acid in particle-induced osteolysis
Biomaterials
(6/2005) - et al.
Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty
Bone
(7/2003) - et al.
The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties
Acta Orthop Scand
(8/2000) - et al.
Preventing fractures in elderly people
BMJ
(7/12/2003) - et al.
Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients
Acta Orthop Scand
(12/2000) - et al.
Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients
Acta Orthop
(12/2007) - et al.
Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients
Acta Orthop
(12/2006)
Use of bisphosphonates to improve the durability of total joint replacements
J Am Acad Orthop Surg
The Danish Hip Arthroplasty Register
Acta Orthop Scand
Registration in the Danish Hip Arthroplasty Registry: completeness of total hip arthroplasties and positive predictive value of registered diagnosis and postoperative complications
Acta Orthop Scand
Epidemiology. When an entire country is a cohort
Science
The Danish National Hospital Register. A valuable source of data for modern health sciences
Dan Med Bull
The impact of confounder selection criteria on effect estimation
Am J Epidemiol
Cited by (59)
Bisphosphonate Use May be Associated With an Increased Risk of Periprosthetic Hip Fracture
2024, Journal of ArthroplastyThe association between bisphosphonate use and aseptic revision risk in primary elective shoulder arthroplasty
2021, Seminars in Arthroplasty JSESCitation Excerpt :Osteoporosis is considered to be a significant risk factor for early revision of total joint arthroplasty and managing this disease process could have significant benefits for the overall survival of the prosthesis.40,41 Bisphosphonate utilization in patients who undergo hip and knee arthroplasty can prevent periprosthetic bone resorption, decrease implant migration, and reduce the risk of all-cause and aseptic revision of the implants.29,38,44,52,56,57,64,66 Literature on bisphosphonate use and revision risk following primary shoulder arthroplasty is lacking.
Unrecognized Osteoporosis Is Common in Patients With a Well-Functioning Total Knee Arthroplasty
2019, Journal of ArthroplastyCitation Excerpt :Treatment with anti-osteoporosis medications has demonstrated clinical benefit following total joint arthroplasty. Bisphosphonate administration has been found to lower risk of fracture after total joint arthroplasty [14] as well as decrease revision rates after total hip arthroplasty (THA) [15]. A recent meta-analysis of 4 studies found long-term use of bisphosphonates to correlate with reduced revision rates after THA and TKA [16].
Mediating bone regeneration by means of drug eluting implants: From passive to smart strategies
2017, Materials Science and Engineering CCitation Excerpt :Rapid development of such approaches have led to advanced and refined solutions that provide mechanically stable and reliable implant solutions. However, still considerable re-operation rates are reported at later follow-ups involving persistent symptoms, progression of degenerative changes, non-healing damages, implant loosening, infection and antimicrobial resistance associated problems; the latter has been recognized among the top three issues affecting human health [6–8]. Moreover, current bone fracture treatments largely fail to address open fractures and critical size bone defects when the natural healing process is impaired and external intervention is required for large defect healing and union.